<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; pipeline</title>
	<atom:link href="http://www.tapanray.in/tag/pipeline/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Any Threat To Current Commercial Model Of ‘Gene Therapy’?</title>
		<link>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=any-threat-to-current-commercial-model-of-gene-therapy</link>
		<comments>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/#comments</comments>
		<pubDate>Mon, 30 Dec 2019 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CAR-T]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[current]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[disorders]]></category>
		<category><![CDATA[dynamics]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[genetic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[pipeline]]></category>
		<category><![CDATA[pricey]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[threat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9833</guid>
		<description><![CDATA[Wish All My Readers A Very Happy, Healthy, Peaceful and Prosperous 2020 &#160; One of the most complex areas in disease management, is the ailments related to genetic disorders. As these were incurable, over the last four decades, medical researchers &#8230; <a href="http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dry New Antibiotic Pipeline: Increasing Incidence Of Deadly Antibiotic Resistance</title>
		<link>http://www.tapanray.in/dry-new-antibiotic-pipeline-increasing-incidence-of-deadly-antibiotic-resistance/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dry-new-antibiotic-pipeline-increasing-incidence-of-deadly-antibiotic-resistance</link>
		<comments>http://www.tapanray.in/dry-new-antibiotic-pipeline-increasing-incidence-of-deadly-antibiotic-resistance/#comments</comments>
		<pubDate>Mon, 23 Jan 2017 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[antibiotic]]></category>
		<category><![CDATA[Antimicrobial]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[dry]]></category>
		<category><![CDATA[iChip]]></category>
		<category><![CDATA[imidazolium oligomers]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[pew]]></category>
		<category><![CDATA[pipeline]]></category>
		<category><![CDATA[PLOS]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[resistance]]></category>
		<category><![CDATA[Singapore]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Teixobactin]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8054</guid>
		<description><![CDATA[On January 13, 2017, &#8216;The Telegraph&#8217; quoting the ‘Centers for Disease Control and Prevention (CDC)’ reported that a woman in Nevada was killed by a superbug that proved resistant to every antibiotic available in the United States (US). She was in her &#8230; <a href="http://www.tapanray.in/dry-new-antibiotic-pipeline-increasing-incidence-of-deadly-antibiotic-resistance/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dry-new-antibiotic-pipeline-increasing-incidence-of-deadly-antibiotic-resistance/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Stakeholder-Mix Has Changed, But Pharma Marketing Has Not</title>
		<link>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-stakeholder-mix-has-changed-but-pharma-marketing-has-not</link>
		<comments>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/#comments</comments>
		<pubDate>Mon, 13 Jun 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[captains]]></category>
		<category><![CDATA[category]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[multi-stakeholder]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[pipeline]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recasting]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[serving]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7670</guid>
		<description><![CDATA[“We try never to forget that medicine is for the people. It is not for profit. Profits follow, and if we have remembered that, they never fail to appear.” In 1952, George Wilhelm Herman Emanuel Merck, the then President of &#8230; <a href="http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
